Head-To-Head Review: Artelo Biosciences (NASDAQ:ARTL) versus Genus (OTCMKTS:GENSF)

Artelo Biosciences (NASDAQ:ARTL) and Genus (OTCMKTS:GENSF) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Insider and Institutional Ownership

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 29.7% of Genus shares are held by institutional investors. 6.9% of Artelo Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Artelo Biosciences and Genus’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$9.29 million	($3.14)	-0.43
Genus	N/A	N/A	N/A	$0.48	58.84

Artelo Biosciences is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Artelo Biosciences and Genus’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-61.68%	-58.15%
Genus	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings for Artelo Biosciences and Genus, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	0	0	1	0	3.00
Genus	0	0	0	0	N/A

Artelo Biosciences currently has a consensus price target of $5.00, indicating a potential upside of 270.37%. Given Artelo Biosciences’ higher possible upside, equities analysts clearly believe Artelo Biosciences is more favorable than Genus.

Summary

Genus beats Artelo Biosciences on 5 of the 8 factors compared between the two stocks.

About Artelo Biosciences

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.

About Genus

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.